Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Genmab A/S today announced changes to its Executive Committee to support Genmab’ s growth and evolution into a fully integrated biotech innovation powerhouse. Genmab’ s Executive Committee ...

Royalty revenue was $1,378 million in the first six months of 2025 compared to $1,111 million in the first six months of 2024, an increase of $267 million, or 24%. The increase in royalties was driven ...

Genmab. "We must, however, continue to focus on Genmab's core competency of antibody creation, development and innovation. Today's reorganization is a key step in our commitment to our updated ...

Danish biotechnology company Genmab will acquire U.S. ProfoundBio for $1.8 billion in cash as it looks to bolster its pipeline of cancer treatments. The acquisition will give Genmab worldwide ...